bluebird bio
60 Binney St
Cambridge
MA
02142
United States
Tel: 339-499-9300
Website: http://www.bluebirdbio.com/
Email: info@bluebirdbio.com
About bluebird bio
bluebird bio is leading the gene therapy revolution. We have nearly 15 years of scientific and clinical experience at the forefront of gene therapy, with deep expertise in rare diseases and immuno-oncology, a proven scientific and lentiviral-based manufacturing platform, and a complementary set of tools such as gene editing.
We are a patient- and purpose-driven, product-oriented organization. Our diverse flock of bluebirds is united by a singular focus: a passionate commitment to changing the lives of patients and supporting each other on this journey. At bluebird bio, we will work like crazy with a never-give-up, little-but-mighty attitude, as exemplified by our namesake, the Eastern Bluebird.
we are always innovating, never stopping and never giving up.
Stock symbol: BLUE
Stock exchange: NASDAQ
Our birds are constantly reminded of the difference they can make on the lives of patients and in the lives of their fellow birds – no matter what their title may be. Whether it’s running a successful experiment in the lab, developing a new and efficient process for your team, being an inspiring mentor for those around you, or always being a friendly face in the morning, we can all make an impact and we can all make a difference. How will you Make Your Mark?
227 articles with bluebird bio
-
The two biggest areas for biotech startups in the U.S. are Cambridge in Boston and the San Francisco Bay Area. They’re also the locations of astonishingly expensive real estate. But they’re where biotechs seem to want to be because they’re close to talent, academic research institutions, and the ...
-
In May the U.S. Food and Drug Administration approved Amgen’s preventative migraine treatment Aimovig. Amgen and its developmental partner Novartis, said the medication would be ready within one week for patients.
-
bluebird bio Presents Updated Data from Phase 2/3 Starbeam Study of Investigational Lenti-D™ Gene Therapy for CALD and Initial Data from Observational Study ALD-103 of Allogeneic Hematopoietic Stem Cell Transplant in CALD at 2018 SSIEM
9/5/2018
Updated Efficacy and Safety Data Consistent with Previously Reported Phase 2/3 Starbeam Results
-
2018 Veeva R&D Summit to Showcase Advances for Speeding Product Development
9/5/2018
More than 100 life sciences experts will share best practices to unify processes in clinical, regulatory, and quality
-
Top 12 Biotech Companies Hiring Now
9/5/2018
Summer is coming to an end, but the job front is still sizzling. Check out the top companies who are looking for candidates like you right now! -
bluebird bio to Present at Investor Conferences in September 2018
8/29/2018
bluebird bio, Inc. today announced that members of the management team will present at the following upcoming investor conferences:
-
bluebird bio and Gritstone Oncology Announce Strategic Collaboration to Develop Novel Cancer Cell Therapies
8/23/2018
bluebird bio, Inc. and Gritstone Oncology, Inc. today announced a collaboration to research, develop and commercialize products for the treatment of cancer using cell therapy.
-
Cambridge, Mass.-based bluebird bio and Gritstone Oncology inked a deal to combine gene and cell therapies to target cancer. This morning California-based Gritstone said it will leverage its artificial intelligence platform, dubbed EDGE, to analyze specific tumor types for the collaboration.
-
Express Scripts is already known for its role of bringing prescriptions to the doors of consumers. Now the company is moving into a new area of providing medicines—expensive gene therapies.
-
Regeneron and bluebird bio Announce Collaboration to Discover, Develop and Commercialize New Cell Therapies for Cancer
8/6/2018
Regeneron Pharmaceuticals, Inc. and bluebird bio, Inc. announced a collaboration to apply their respective technology platforms to the discovery, development and commercialization of novel immune cell therapies for cancer.
-
bluebird bio and Regeneron Announce Collaboration to Discover, Develop and Commercialize New Cell Therapies for Cancer
8/6/2018
The collaborators will specifically leverage Regeneron’s VelociSuite® platform technologies for the discovery and characterization of fully human antibodies
-
Regeneron Pharmaceuticals and bluebird bio are teaming up. The companies will combine their expertise in the battle against cancer by leveraging Regeneron’s VelociSuite platform with bluebird’s cell therapy technologies to develop new cell therapies for patients.
-
This week, the Business Journals compiled a list of the 25 companies across the United States with the highest median salary for employees. According to the list, median salaries for these companies ranked from $198,000 to $495,000. Of those companies listed, more than half were in the pharma or ...
-
bluebird bio to Present at the 2018 Wedbush PacGrow Healthcare Conference
8/3/2018
bluebird bio, Inc. announced that members of the management team will present at the 2018 Wedbush PacGrow Healthcare Conference, Tuesday, August 14, at 8:35 a.m. ET at the Parker New York Hotel, New York City.
-
bluebird bio to Present Updated Data for Lenti-D™ Gene Therapy for Cerebral Adrenoleukodystrophy at SSIEM 2018 Symposium
8/3/2018
Data Include Updates from Phase 2/3 Starbeam (ALD-102) Study of Lenti-D for Cerebral Adrenoleukodystrophy (CALD) and Initial Data from Ongoing Observational Study (ALD-103) of Allogeneic Hematopoietic Stem Cell Transplant for CALD
-
bluebird bio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
7/27/2018
bluebird bio, Inc. (Nasdaq: BLUE) today announced the closing of its previously announced underwritten public offering of 3,892,308 shares of its common stock, including 507,692 shares of common stock sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a public offering price of $162.50 per share.
-
bluebird bio’s LentiGlobin™ Gene Therapy Granted Accelerated Assessment by European Medicines Agency for the Treatment of Transfusion-Dependent β-Thalassemia
7/26/2018
bluebird bio, Inc. (Nasdaq: BLUE) today announced that its investigational LentiGlobin™ gene therapy for the treatment of adolescent and adult patients with transfusion-dependent β-thalassemia (TDT) and a non-β0/β0 genotype, was granted an accelerated assessment by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), for its upcoming marketing authorization application (MAA).
-
bluebird bio Announces Pricing of 3,384,616 Shares of Its Public Offering of Common Stock
7/25/2018
bluebird bio, Inc. announced the pricing of an underwritten public offering of 3,384,616 shares of its common stock at a public offering price of $162.50 per share
-
bluebird bio Announces Proposed Public Offering of $400 Million of Its Common Stock
7/23/2018
bluebird bio, Inc. announced that it has commenced an underwritten public offering of $400 million of its common stock.
-
Precision BioSciences CSO to Join Gene Therapy Session at DIA 2018
6/20/2018
Precision BioSciences CSO Derek Jantz will present and join a panel discussion during the DIA (Drug Information Association) 2018 conference.